Research programme: metabolic disorder therapeutics - HemoShear Therapeutics
Latest Information Update: 17 Oct 2016
At a glance
- Originator HemoShear
- Developer Childrens National Health System; HemoShear Therapeutics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Acidaemia; Non-alcoholic steatohepatitis
Most Recent Events
- 15 Jun 2015 Early research in Acidaemia in USA (unspecified route)
- 15 Jun 2015 Early research in Non-alcoholic steatohepatitis in USA (unspecified route)